Evgen Pharma PLC Preclinical data on a new therapeutic target (5197M)
22 Gennaio 2021 - 8:00AM
UK Regulatory
TIDMEVG
RNS Number : 5197M
Evgen Pharma PLC
22 January 2021
Evgen Pharma plc
("Evgen" or "the Company" or "the Group")
Preclinical data on a new therapeutic target for SFX-01
Lead candidate SFX-01 inhibits SHP2, a protein associated with a
number of different cancer types
Evgen Pharma plc (AIM: EVG), the clinical stage drug development
company developing sulforaphane based medicines for the treatment
of multiple diseases, announces preclinical data demonstrating that
SFX-01 is an inhibitor of SHP2.
SHP2 (Src homology-2 domain-containing protein tyrosine
phosphatase-2) is a non-receptor protein tyrosine phosphatase that
is associated with breast cancer, leukaemia, lung cancer, liver
cancer, gastric cancer, laryngeal cancer, oral cancer and other
cancer types.
In-vitro and in-vivo data generated by Professor Philip Eaton,
Queen Mary University of London, demonstrates that SFX-01 modifies
SHP2, inhibiting its phosphatase activity; this phosphatase is
implicated in many aspects of cancer . SHP2 is involved in several
cancer-related processes, including cancer cell invasion and
metastasis, apoptosis, DNA damage, cell proliferation, cell cycle
and drug resistance. SHP2 may therefore be a therapeutic target of
great potential.
This exciting data provides another pathway through which SFX-01
may be a valuable anti-cancer agent in addition to its effects on
the STAT3 pathway, thought to be the principal mechanism of action
in metastatic breast cancer.
Further preclinical work is being conducted in cancer models and
data will be announced in due course.
Dr Huw Jones, CEO of Evgen Pharma, commented: "SHP2 has been a
target of some interest for a while, but to date attempts to
develop an inhibitor have had limited success. We are delighted
that the data generated by Professor Eaton demonstrates that SFX-01
acts on SHP2 in a novel manner and offers the potential for its use
in a number of cancers with great clinical need."
Enquiries:
Evgen Pharma plc www.evgen.com via Walbrook
--------------------------------------
Dr H uw Jones CEO
--------------------------------------
Richard Moulson, CFO
--------------------------------------
finnCap www.finncap.com +44 (0) 20 7220 0500
--------------------------------------
Geoff Nash / Teddy Whiley (Corporate
Finance)
--------------------------------------
Alice Lane, Manasa Patil (ECM)
--------------------------------------
Walbrook PR +44 (0)20 7933 87870 or evgen@walbrookpr.com
--------------------------------------
+44 (0)7980 541 893 / +44 (0)7876 741
Paul McManus / Anna Dunphy 001
--------------------------------------
About Evgen Pharma plc
Evgen Pharma is a clinical stage company developing sulforaphane
based medicines for the treatment of multiple diseases The
Company's core technology is Sulforadex (R), a method for
synthesising and stabilising the naturally occurring compound
sulforaphane and novel proprietary analogues based on sulforaphane.
The lead product, SFX-01, is a patented composition of synthetic
sulforaphane and alpha-cyclodextrin.
The Company commenced operations in January 2008 and has its
headquarters at The Colony, Wilmslow, Cheshire, and its registered
office is at the Liverpool Science Park, Liverpool. Our lead
product, SFX-01, has demonstrated efficacy in a Phase II trial for
advanced metastatic breast cancer. It has been used to treat over
150 patients in clinical trials and is well-tolerated with
predominately mild side-effects.
Evgen shares are traded on the AIM market of the London Stock
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RESUAONRABUAUAR
(END) Dow Jones Newswires
January 22, 2021 02:00 ET (07:00 GMT)
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Lug 2023 a Lug 2024